4 Result: AstraZeneca
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
September 04th, 2026
Silver Spring, MD / CRWE PRESS RELEASE / September 04, 2026 - The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innov. Read more
Earnings Preview: Key Expectations for AstraZeneca, Nucor, Celestica
July 25th, 2026
LAS VEGAS, NV / CRWE PRESS RELEASE / July 25, 2026 - Several companies are expected to unveil their financial results on Monday, July 27, including: AstraZeneca PLC (NYSE: AZN), the global biopharmaceutical company known for its portfolio of oncol. Read more
AstraZeneca, AMSC, Lifecore Biomedical, Arbor Realty Trust: Biotech News, Bullish Perceptions
June 04th, 2023
AstraZeneca's (Nasdaq: AZN) announced that TAGRISSO (osimertinib) has demonstrated a significant improvement in overall survival (OS) in patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).&nb. Read more
Q1 2023 Earnings Report: KE Holdings and Bath & Body Works Exceed Expectations, Sociedad Química y Minera de Chile Falls Short; Revvity Inks Licensing Deal with AstraZeneca
May 18th, 2023
KE Holdings Inc. (NYSE: BEKE) reported better-than-expected adjusted earnings per share (EPS) for the first quarter of 2023. The company's adjusted EPS stood at $0.43, surpassing the consensus estimate of $0.23. In pre-market trading, $BEKE . Read more
Want To Find Some News?
News By Industries
Recent Post
-
September 23rd, 2026
FTC Endorses Education Department Proposal to Expand Higher Education Accreditation Options
September 22nd, 2026September 18th, 2026FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026
Member Login